Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)


Interview Clean Logistics: Hydrogen challenge to Daimler + Co.

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".

Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".

30. June 2021 | 12:59 CET

CureVac, Cardiol Therapeutics, MorphoSys - Here it is going powerfully upwards!

  • Biotechnology
Photo credits:

Biotech stocks offer investors not only an exciting but also a very profitable investment environment. But the sector is also attractive for traders due to its high volatility. CureVac took a beating recently as the efficacy of its Corona vaccine disappointed. The price of MorphoSys falls despite good news and positive analyst comments. The Canadian Cardiol Therapeutics could be on the verge of a revaluation. Where can the most significant gains be made in the short term?

time to read: 3 minutes by Carsten Mainitz
ISIN: CUREVAC N.V. O.N. | NL0015436031 , CARDIOL THERAPEUTICS | CA14161Y2006 , MORPHOSYS AG O.N. | DE0006632003



Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author

CUREVAC NV - The countdown is on

In mid-June, German biotech Company CureVac provided information on its first-generation Corona vaccine candidate, announcing that a preliminary evaluation showed the compound had an efficacy of around 47%. This announcement hit like a bomb. As a result, the share price fell by half. In the meantime, the shares have recovered somewhat to around EUR 54.

The sharp drop was due to the significantly lower efficacy of the vaccine compared to competitors' preparations. In addition, the vaccine has not yet been approved. Astra Zeneca, BioNTech/Pfizer, Moderna and Johnson & Johnson are currently dividing the cake among themselves. Those who are too late may only have a few crumbs left.

Now the CEO of the Tübingen-based vaccine developer CureVac, Franz-Werner Haas, has spoken out. Haas expects final results from the pivotal study phase very soon. "It won't take more than a week or ten days. We expect the results in the short term," Haas said Monday at a press conference. Like BioNTech and Moderna, CureVac relies on mRNA technology. However, the Tübingen-based Company is pursuing a slightly different approach. Haas remained convinced that the vaccine could be approved. Amsterdam's European Medicines Agency (EMA) initiated a rapid review process for the Tübingen-based Company's vaccine in February. The federal government also has a vested interest in the South German Company's success for two reasons. First, because the vaccine is firmly scheduled for a later vaccination campaign, and second, the federal government has invested EUR 300 million in CureVac through Aufbaubank KfW and holds a 16% stake.

CARDIOL THERAPEUTICS INC - When will the revaluation start?

Cardiol Therapeutics is breaking new ground in inflammatory heart disease therapy. The Canadians are relying on cannabidiol (CBD) for therapeutic trials. A body of scientific evidence exists that suggests the use of cannabidiol as an anti-inflammatory agent is beneficial. The Company has an exclusive manufacturing agreement for a pharmaceutical cannabidiol formulation that is highly concentrated and THC-free. In April, Cardiol enrolled the first patients in LANCER for a Phase II/III outcomes study in high-risk patients treated with Covid-19. The single and multiple ascending dose Phase I clinical trial showed successful topline results for CardiolRx in April. The Company filed for listing on NASDAQ in March 2021. Trading on the NASDAQ is expected to result in a significant valuation boost for the stock.

Characteristically, companies like Cardiol operate at a loss in the early stages. The potential of the existing product pipeline and the management team's expertise enabled the Company to raise more than CAD 50 million on the capital market in the last 12 months. That is a considerable house number. The analysts of GBC certify the Company in the case of success, enormous profits, and formulate a price target of CAD 15.77 - a potential fivefold! In addition, the analysts classify the Company as a takeover target in case of positive results of the Covid-19 phase II/III trials. Currently, the shares are trading around CAD 3, giving the Company a market capitalization of CAD 127 million.


In recent months, the MorphoSys share has only known reverse gear. While the shares were still quoted at EUR 120 last summer, only EUR 68 per share is called up. The Company is thus valued at EUR 2.2 billion. The acquisition of NASDAQ-listed Constellation Pharmaceuticals Inc. for USD 34 per share in cash, announced in June, failed to give the share price any positive impetus. Analysts see clear upside potential for the German stock, but that is not helping at the moment. Perhaps a cancer drug that the US pharmaceutical Company Incyte is marketing together with MorphoSys will soon revive the share price. Incyte has concrete hopes of obtaining approval for its blood cancer drug tafasitamab in Europe. As reported last Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive recommendation for the drug. If marketing is then made possible in the next step, this should be reflected in rising share prices.


Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

21. October 2021 | 12:17 CET | by Stefan Feulner

Sartorius, Defence Therapeutics, QIAGEN - Still long potential

  • Biotechnology

Since the outbreak of the Corona pandemic, biotech and pharmaceutical shares have been among the top performers on the stock market. In addition to vaccine producers such as BioNTech and Pfizer, the share price of the US pharmaceutical Company Moderna also multiplied. Other winners included diagnostics companies and laboratory equipment suppliers, process technology specialists and manufacturers of biopharmaceuticals. Biopharmaceuticals promise enormous growth potential even after Corona, especially the market such as gene and cell therapies is growing dynamically at the moment.


20. October 2021 | 11:04 CET | by Armin Schulz

Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?

  • Biotechnology

The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.


18. October 2021 | 10:44 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Bayer: Where triple-digit returns beckon

  • Biotechnology

The pandemic is drawing to a close. Vaccination rates are high, and a new wave is - fortunately - not picking up speed. But in this environment, what is happening to many highly acclaimed pandemic stocks? Are vaccine manufacturers still interesting at the moment? We look at how the industry is faring and where opportunities can still be found.